Answering Key Questions About COVID-19 Vaccines

Corresponding Author: Jesse L. Goodman, MD, MPH, Medicine and Infectious Disease, Georgetown University School of Medicine, 3900 Reservoir Rd, Washington, DC 20057 (jesse.goodman@georgetown.edu).

Published Online: October 16, 2020. doi:10.1001/jama.2020.20590

Conflict of Interest Disclosures: Dr Goodman reported receiving personal fees and nonfinancial support from GlaxoSmithKline and Intellia Therapeutics, and nonfinancial support from US Pharmacopeia outside the submitted work. Dr Grabenstein reported having stock equity in Merck & Co, consulting fees from Valneva, personal fees from serving on the Janssen advisory board, and personal fees from the VBI advisory board outside the submitted work. No other disclosures were reported.

Additional Contributions: We thank Norman W. Baylor, PhD, Biologics Consulting; Luciana L. Borio, MD, In-Q-Tel; Bruce G. Gellin, MD, MPH, Sabin Vaccine Institute; Peter J. Hotez, MD, PhD, Baylor College of Medicine; Glen J. Nowak, PhD, University of Georgia; Paul A. Offit, MD, Children’s Hospital of Philadelphia; and Walter A. Orenstein, MD, Emory University, for their input and Nicole Lurie, MD, MSPH, Coalition for Epidemic Preparedness Innovations (CEPI), Harvard Medical School, for her helpful review.

Additional Information: Dr Goodman reported that he served as the chief scientist of the FDA from January 2009 to March 2014.